Opinion|Videos|November 18, 2026

Disease Biology vs Patient Context: Selecting Treatment at First Relapse in Relapsed/Refractory Multiple Myeloma

Teams Catalyst and Compass continue their debate on whether disease biology or patient context should primarily guide treatment selection at first relapse in relapsed/refractory multiple myeloma.

Episodes in this series

Teams Catalyst and Compass continue their debate on whether disease biology or patient context should primarily guide treatment selection at first relapse in relapsed/refractory multiple myeloma. Dr. Peter Forsberg reinforces the importance of assessing disease biology, including relapse patterns and disease behavior, to identify patients who may require a particular therapeutic approach. Team Compass emphasizes how comorbidities, treatment tolerability, logistical barriers, and individual circumstances can limit available options and influence treatment decisions. Faculty also discuss the importance of shared decision-making, noting that incorporating patient preferences allows clinicians to explain the available treatment options and involve patients in selecting an approach aligned with their needs and goals. The discussion acknowledges that comparative evidence to establish the optimal sequencing of CELMoD-based regimens and T-cell-redirecting therapies remains limited. Faculty highlight the physician’s role in communicating the rationale for treatment recommendations while balancing the biological characteristics of the disease with the patient’s circumstances and preferences.


Related to this article